NTRA Earnings Date: Nov 5, 2026 (Estimated) — Natera, Inc.
NASDAQ · Healthcare · Medical - Diagnostics & Research
Updated
When is NTRA's next earnings date?
Natera, Inc. (NTRA) is expected to report Q3 2026 earnings on Thursday, November 5, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.28 on revenue of $707.5M.
How did NTRA do in its last earnings report?
In its most recent report on Aug 6, 2026 (Q2 2026), Natera, Inc. posted EPS of -$0.47 versus the -$0.49 estimate, a beat of 9.6%. Revenue was $752.8M against a $661.2M estimate. The stock's 1-day post-earnings move was +21.4%.
How much does NTRA stock move after earnings?
NTRA beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 8.9% (up or down) in the day after earnings.
About Natera, Inc.
Natera, Inc. is a diagnostics company focused on developing and commercializing a wide array of molecular testing services globally. Its portfolio includes several key offerings: Panorama, a non-invasive prenatal test (NIPT) that screens for chromosomal abnormalities in a fetus using a blood sample from the mother, and also determines zygosity in twin pregnancies. Vistara, designed to identify single-gene disorders by screening for specific single-gene mutations. Horizon, a comprehensive carrier screening test to determine an individual's carrier status for various genetic diseases. Spectrum, utilized during in vitro fertilization (IVF) cycles to detect chromosomal anomalies or inherited genetic conditions. Anora, a miscarriage analysis product that examines fetal chromosomes to help understand the cause of pregnancy loss. Non-invasive paternity testing, which establishes paternity during gestation using blood samples from both the pregnant mother and the alleged father. Beyond reproductive health, Natera also provides specialized tests: Signatera, a sophisticated circulating tumor DNA (ctDNA) technology capable of screening for a generic set of mutations, independent of the individual's specific tumor characteristics. Prospera, a test used to assess and monitor organ transplant rejection. Additionally, the company offers Constellation, a cloud-based software platform that provides laboratory clients with access to Natera's proprietary algorithms and bioinformatics, enabling them to validate and launch their own tests. Natera distributes its products through a direct sales team and an extensive network of approximately 100 laboratory and distribution partners. The company has strategic partnerships, including one with BGI Genomics Co., Ltd. for the development, manufacturing, and commercialization of NGS-based genetic testing assays, and another with Foundation Medicine, Inc. to develop and commercialize personalized circulating tumor DNA monitoring assays. Founded in 2003, Natera, Inc. is headquartered in Austin, Texas. It was formerly known as Gene Security Network, Inc. before changing its name in 2012.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-06 | Q2 2026 | -0.49 | -0.47 | +9.62% | $752.8M | ✅ Beat | +21.37% | +17.11% | +23.66% |
| 2026-05-07 | Q1 2026 | -0.55 | -0.60 | -9.09% | $696.6M | ❌ Miss | -11.64% | -10.42% | -2.89% |
| 2026-02-26 | Q4 2025 | -0.50 | 0.36 | +172.00% | $665.5M | ✅ Beat | -3.73% | -8.77% | -15.48% |
| 2025-11-06 | Q3 2025 | -0.37 | -0.64 | -72.97% | $592.2M | ❌ Miss | +0.55% | +1.10% | +20.49% |
| 2025-08-07 | Q2 2025 | -0.60 | -0.74 | -23.33% | $546.6M | ❌ Miss | +7.70% | +12.31% | +18.65% |
| 2025-05-08 | Q1 2025 | -0.66 | -0.50 | +24.24% | $501.8M | ✅ Beat | -6.53% | -8.10% | +1.00% |
| 2025-02-27 | Q4 2024 | -0.39 | -0.41 | -5.13% | $476.1M | ❌ Miss | -0.65% | -9.65% | -8.09% |
| 2024-11-12 | Q3 2024 | -0.57 | -0.26 | +54.39% | $439.8M | ✅ Beat | +19.13% | +19.97% | +23.19% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $748.2M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Product | 100.0% | $747.9M | +37.4% | $884.3M | $500.0M | $544.4M | $590.2M |
| Oncology | 0.0% | $300K | — | — | — | — | — |
By region
Q2 FY26 · $752.8M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 98.2% | $739.5M | — | — | — | — | — |
| EMEA | 1.2% | $9.0M | — | — | — | — | — |
| Americas, Excluding United States | 0.3% | $2.2M | — | — | — | — | — |
| Asia Pacific And Other | 0.3% | $2.0M | — | — | — | — | — |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.